Indication
FIRAZYR® (icatibant injection) is a medicine used to treat acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Important Safety Information
Laryngeal attacks can become life threatening. If you have an HAE attack of the throat (laryngeal attack), inject FIRAZYR and then go to the nearest hospital emergency room right away.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
Welcome to FIRAZYR

FIRAZYR® (icatibant injection) is the first FDA-approved injection you give yourself under the skin (subcutaneously) to treat acute attacks of HAE—both in and out of the home—after you have been trained by a healthcare professional.

This brochure is a guide to help you learn about:

• How FIRAZYR can be a key part of your HAE treatment plan
• How to treat HAE attacks with FIRAZYR
• The personalized OnePath® product support services offered to eligible patients who have been prescribed FIRAZYR

Important Safety Information

The most common side effects of FIRAZYR include:

• redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site
• fever
• too much of an enzyme called transaminase in your blood
• dizziness
• nausea
• headache
• rash

These are not all of the possible side effects of FIRAZYR. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
Guidelines recommend that acute therapy be a part of every HAE treatment plan

Current guidelines recommend that people with HAE have an acute therapy as part of their treatment plan, so they are always prepared to treat if an unexpected attack occurs. **Guidelines also support exploring both preventive and acute therapy as part of a treatment plan.** People with HAE should be evaluated for long-term preventive treatment at every doctor’s visit, or at least once a year.

People with HAE, including those taking a preventive therapy, are strongly encouraged to have enough acute treatment for 2 attacks, or at least 2 doses, on hand to be prepared if an attack happens.

**Guidelines also recommend that acute treatment of HAE attacks should be administered:**

- As early as possible in an attack
- For all attacks, regardless of location, as soon as they are clearly recognized

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
Treat HAE attacks both in and out of the home

**FIRAZYR® (icatibant injection) is a portable acute therapy option for adults that can go wherever you go, so you are always prepared to treat an attack if needed**

FIRAZYR is supplied as a 3-mL, prefilled, single-use syringe and is self-administered under the skin (subcutaneously) in the abdomen or stomach area.

- You may self-administer FIRAZYR after training by a healthcare professional

If your symptoms are not resolved or if symptoms occur again after your first dose of FIRAZYR, additional doses can be administered at least 6 hours apart (no more than 3 doses in any 24-hour period).

**FIRAZYR does not need refrigeration or special handling**

- Store between 36°F to 77°F (2°C to 25°C)
- Do not freeze
- Keep FIRAZYR in the original carton until you are ready to use it
- No mixing needed

**Important Safety Information**

Tell your healthcare provider if you have any other medical conditions, if you are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. FIRAZYR has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if FIRAZYR is right for you.
Proven treatment that’s ready if an unexpected attack occurs

FIRAZYR® (icatibant injection) can be used to treat all types of acute HAE attacks, including skin (cutaneous), stomach (abdominal), and throat (laryngeal).

In the pivotal trial (Trial 1), the median time to 50% reduction in symptoms of cutaneous or abdominal attacks was 2.0 hours for those treated with FIRAZYR vs 19.8 hours for those given placebo.

In Trial 1, the median time to almost complete symptom relief was 8.0 hours vs 36.0 hours for FIRAZYR and placebo, respectively.

Across 3 controlled clinical trials, median time to 50% reduction from baseline symptoms ranged from 2.0 to 2.3 hours with FIRAZYR.

In clinical trials, 9 out of 10 attacks were treated with a single dose of FIRAZYR.

In controlled studies:
FIRAZYR was used to treat acute HAE attacks of the throat in 60 people. Symptom reduction was similar to results seen for skin and abdominal attacks. It is important to know that laryngeal (throat) attacks can become life-threatening. If you have an HAE attack involving the throat, inject FIRAZYR as directed and then go to the nearest hospital emergency room right away.

I felt the beginnings of an HAE attack and, thankfully, I had FIRAZYR in my bag and treated immediately. I'm proud that by treating the attacks quickly, my symptoms subsided.

—A real HAE patient
How does FIRAZYR work?

Most people with HAE either don’t have enough proteins in the kallikrein-kinin system or the proteins do not work as they should, including C1 esterase inhibitor (C1-INH) and plasma kallikrein. This triggers the release of bradykinin. Increased bradykinin levels cause blood vessels to release fluid, resulting in the localized swelling and pain of an HAE attack.

FIRAZYR works by blocking bradykinin from binding to B2 receptors, which reduces the activity of bradykinin and thereby treats the symptoms of an acute HAE attack.

Important Safety Information

If your symptoms continue or come back, you may repeat your FIRAZYR injection at least 6 hours apart. Do not use more than 3 doses of FIRAZYR in a 24-hour period.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
Recognizing the symptoms of an HAE attack

HAE can cause attacks of swelling in any part of the body, but the most common locations include the skin (e.g., face, hands, feet, genitals), abdomen, and throat.

**Skin, or cutaneous**
- Swelling of the skin usually affects the hands, feet, face, or genitals
- Can be temporarily disfiguring and disabling and get in the way of everyday activities
- May be accompanied by redness, but the area usually doesn’t itch

**Stomach, or abdomen**
- Can cause mild to severe pain
- May be accompanied by vomiting and/or diarrhea
- Some people required bed rest for 24 to 50 hours due to their untreated abdominal attacks

**Throat, or larynx**
- Causes swelling in the throat, also called a laryngeal attack
- Swelling in the throat can interfere with breathing, creating a potentially life-threatening situation
- May cause other symptoms, such as voice changes and difficulty swallowing

Before an attack, some people with HAE experience early warning signs, also called prodromal symptoms, such as tingling, rash, fatigue, or nausea.

**Important Safety Information**
Tiredness, drowsiness, and dizziness have been reported following the use of FIRAZYR® (icatibant injection). If this occurs, do not drive a car, use machinery, or do anything that needs you to be alert.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
For eligible patients, FIRAZYR offers access to OnePath® product support services

People who have been prescribed FIRAZYR and have enrolled in OnePath will be connected with a dedicated Patient Support Manager (PSM) who works with them to help ensure they get access to their medication, in addition to providing other services.

With your FIRAZYR treatment, OnePath provides you with:

- **A dedicated PSM** to connect you with important information and resources about FIRAZYR and other Takeda HAE products that are part of your treatment plan

- **Help facilitating** an insurance benefits investigation, and explaining insurance coverage and financial assistance options (if applicable)

- **In-home injection training and support** for you and your caregiver(s) at no cost

- **Educational resources** and the OnePath Mobile App for you and your caregiver(s) at no cost

OnePath also offers the following injection supplies:

- Sharps Recovery System™ container to mail back used syringes and needles for proper disposal

- Pack of Point-Lok® needle caps for covering the needle after injecting FIRAZYR when you don’t have access to your sharps container

Sharps Recovery System and Point-Lok are either trademarks or registered trademarks of their respective owners.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
I carry FIRAZYR with me, whether I’m at home or traveling. That way, the very moment I start to notice swelling, even if it’s in the middle of the night, I can treat.

—A real HAE patient

Additional resources and programs for you

The Takeda speaker programs offer educational events for you and your loved ones to learn more about living with HAE and treatment with the portfolio of HAE products from Takeda.

The types of programs available to you include product programs presented by a healthcare professional and, when available, a patient ambassador will be featured.

Your OnePath PSM can tell you about any upcoming events in your area.

You can also connect with other people living with HAE by reaching out to the US Hereditary Angioedema Association (HAEA) by calling 1-866-798-5598 or emailing mentors@haea.org.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
Common questions about FIRAZYR

What are the possible side effects of FIRAZYR?
The most common side effects of FIRAZYR® (icatibant injection) include redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site; fever; too much of an enzyme called transaminase in your blood; dizziness; nausea; headache; and rash.

When should I take FIRAZYR?
FIRAZYR should be self-administered as soon as you recognize the symptoms of an HAE attack.

Can I give the injection myself?
You or your caregiver can administer FIRAZYR after receiving training from a healthcare professional. OnePath® offers injection training support. At your doctor’s request, a specially trained nurse will take you step by step through the FIRAZYR injection process. You can watch an injection training video online at www.firazyr.com/injectionvideo.

Can I use FIRAZYR for all of my attacks?
Guidelines recommend that you administer your acute treatment as early as possible in an attack and for all attacks, regardless of location, as soon as they are clearly recognized. Laryngeal attacks can become life threatening. If you have an attack in your throat (laryngeal attack), inject FIRAZYR and then go to the nearest hospital emergency room right away.

Can I take other medications with this product?
No studies have been conducted examining the interaction of FIRAZYR with other medications. Because FIRAZYR blocks bradykinin, it may affect how angiotensin-converting-enzyme (ACE) inhibitors work. You should let your doctor know about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements, and if you are taking an ACE inhibitor.

What else should I tell my doctor before taking FIRAZYR?
Tell your doctor if you have any other medical conditions, if you are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. FIRAZYR has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if FIRAZYR is right for you.

Please see complete Important Safety Information on last page and click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.
**Indication**

FIRAZYR® (icatibant injection) is a medicine used to treat acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

**Important Safety Information**

Laryngeal attacks can become life threatening. **If you have an HAE attack of the throat (laryngeal attack), inject FIRAZYR and then go to the nearest hospital emergency room right away.**

The most common side effects of FIRAZYR include:

- redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site
- fever
- too much of an enzyme called transaminase in your blood
- dizziness
- nausea
- headache
- rash

These are not all of the possible side effects of FIRAZYR. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Tell your healthcare provider if you have any other medical conditions, if you are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. FIRAZYR has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if FIRAZYR is right for you.

If your symptoms continue or come back, you may repeat your FIRAZYR injection at least 6 hours apart. Do not use more than 3 doses of FIRAZYR in a 24-hour period.

Tiredness, drowsiness, and dizziness have been reported following the use of FIRAZYR. If this occurs, do not drive a car, use machinery, or do anything that needs you to be alert.

**Please click here for Full Prescribing Information, including Patient Information, which is also available at www.firazyr.com.**